How useful is bone marrow study as an initial investigative tool without lymph node biopsy in malignant lymphoma?: Eleven years of experience at a single institution

Kwoun, Woo-Jae; Ahn, Jeong Yeal; Park, Pil-Whan; Seo, Yiel-Hea; Kim, Kyung‐Hee; Seo, Ja Young; Lee, Hwan Tae; Yoo, Kuai-Han

doi:10.1002/jcla.22841

Cited by 4 publications

(4 citation statements)

References 17 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, the diagnosis of ABC DLBCL was established through a bone biopsy. A previous study revealed that different diagnoses can be made by examining lymph node biopsies and other sites of involvement, and the diagnosis concordance rate between bone marrow and lymph nodes was 84.85% ( 28 ). Most patients with discordant bone marrow involvement (BMI) progress to invasive lymphoma due to transformation of the original indolent neoplasm or benign lymphoid aggregation, and downgrading from high- to low-grade malignancy has also been observed.…”

Section: Discussionmentioning

confidence: 99%

Hemophagocytic lymphohistiocytosis as an onset of diffuse large B‑cell lymphoma: A case report

et al. 2022

View full text Add to dashboard Cite

A 53-year-old male presented with a 1-month history of hyperpyrexia. The clinical manifestations revealed hemophagocytic lymphohistiocytosis (HLH). Although a lymph node biopsy could not be obtained, a bone marrow biopsy revealed the activated B-cell subtype of diffuse large B-cell lymphoma (DLBCL). After being treated with HLH-1994 (dexamethasone and etoposide), a rituximab-containing chemotherapy and target agents involving bortezomib, the patient achieved remission. To understand the molecular profile of patient, next-generation sequencing and MYD88 L265P mutation examinations were performed, and the patient was determined to be positive for the MYD88 L265P mutation. Reports of DLBCL with plasmacytic differentiation and a MYD88 innate immune signal transduction adaptor L265P mutation concurrent with HLH are rare. Early recognition, precise diagnosis and timely therapy are pivotal in improving patient prognosis. Furthermore, molecular profiling enables researchers to develop potential therapies aimed at the activated NF-κB and endoplasmic reticulum stress signaling pathways. The present study highlights this pathogenesis and provides suggestions for further individualized therapeutics.

show abstract

Section: Discussionmentioning

confidence: 99%

Hemophagocytic lymphohistiocytosis as an onset of diffuse large B‑cell lymphoma: A case report

et al. 2022

View full text Add to dashboard Cite

show abstract

“…However, bone marrow status assessment cannot be completed entirely by noninvasive means of PET/CT or MRI in clinical practice. Still, it can only be achieved by invasive bone marrow examination, including blood smear, biopsy, and flow cytometry [ 7 , 8 ]. Various differentiated cells such as lymphoid, erythroid, and myeloid cells can be seen in bone marrow smears.…”

Section: Introductionmentioning

confidence: 99%

Prediction Model of Bone Marrow Infiltration in Patients with Malignant Lymphoma Based on Logistic Regression and XGBoost Algorithm

Huang

Chen

Miao

2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

Objective. The prediction model of bone marrow infiltration (BMI) in patients with malignant lymphoma (ML) was established based on the logistic regression and the XGBoost algorithm. The model’s prediction efficiency was evaluated. Methods. A total of 120 patients diagnosed with ML in the department of hematology from January 2018 to January 2021 were retrospectively selected. The training set ( n = 84 ) and test set ( n = 36 ) were randomly divided into 7 : 3, and logistic regression and XGBoost algorithm models were constructed using the training set data. Predictors of BMI were screened based on laboratory indicators, and the model’s efficacy was evaluated using test set data. Results. The prediction algorithm model’s top three essential characteristics are the blood platelet count, soluble interleukin-2 receptor, and non-Hodgkin’s lymphoma. The area under the curve of the logistic regression model for predicting the BMI of patients with ML was 0.843 (95% CI: 0.761~0.926). The area under the curve of the XGBoost model is 0.844 (95% CI: 0.765~0.937). Conclusion. The prediction model constructed in this study based on logistic regression and XGBoost algorithm has a good prediction model. The results showed that blood platelet count and soluble interleukin-2 receptor were good predictors of BMI in ML patients.

show abstract

“…It should be noted that the BM infiltration pattern can be different [4]. BM lesions can be detected using non-invasive diagnostic methods such as MRI and PET-CT, but BM biopsy is also indicated if PET/CT is negative; in some clinical situations, BM biopsy can be the only technique providing data on the presence and degree of BM infiltration with tumor lymphoid cells [5][6][7]. Currently, aspiration cytology and trephine biopsy are believed to complement each other and increase the accuracy of NHL diagnosis [8,9].…”

Section: Introductionmentioning

confidence: 99%

The Profile of MicroRNA Expression in Bone Marrow in Non-Hodgkin’s Lymphomas

et al. 2022

View full text Add to dashboard Cite

Non-Hodgkin’s lymphomas (NHLs) are a heterogeneous group of malignant lymphomas that can occur in both lymph nodes and extranodal sites. Bone marrow (BM) is the most common site of extranodal involvement in NHL. The objective of this study is to determine the unique profile of miRNA expression in BM affected by NHL, with the possibility of a differential diagnosis of NHL from reactive BM changes and acute leukemia (AL). A total of 180 cytological samples were obtained by sternal puncture and aspiration biopsy of BM from the posterior iliac spine. All the cases were patients before treatment initiation. The study groups were NHL cases (n = 59) and AL cases (acute lymphoblastic leukemia (n = 25) and acute myeloid leukemia (n = 49)); the control group consisted of patients with non-cancerous blood diseases (NCBDs) (n = 48). We demonstrated that expression levels of miRNA-124, miRNA-221, and miRNA-15a are statistically significantly downregulated, while the expression level of let-7a is statistically significantly upregulated more than 2-fold in BM in NHL compared to those in AL and NCBD. ROC analysis revealed that let-7a/miRNA-124 is a highly sensitive and specific biomarker for a differential diagnosis of BM changes in NHL from those in AL and NCBD. Therefore, we conclude that analysis of miRNA expression levels may be a promising tool for early diagnosis of NHL.

show abstract

How useful is bone marrow study as an initial investigative tool without lymph node biopsy in malignant lymphoma?: Eleven years of experience at a single institution

Cited by 4 publications

References 17 publications

Hemophagocytic lymphohistiocytosis as an onset of diffuse large B‑cell lymphoma: A case report

Hemophagocytic lymphohistiocytosis as an onset of diffuse large B‑cell lymphoma: A case report

Prediction Model of Bone Marrow Infiltration in Patients with Malignant Lymphoma Based on Logistic Regression and XGBoost Algorithm

The Profile of MicroRNA Expression in Bone Marrow in Non-Hodgkin’s Lymphomas

Contact Info

Product

Resources

About